Revenue

EBITDA

Earnings

Price per share at the end of the period divided by the last reported earnings

Free Cash Flow

Bausch Health Companies Inc., together with its subsidiaries, develops, manufactures, and markets a range of pharmaceutical, medical device, and over-the-counter (OTC) products primarily in the therapeutic areas of eye health, gastroenterology, and dermatology. The company operates through five segments: Bausch + Lomb, Salix, International Rx, Ortho Dermatologics, and Diversified Products. The Bausch + Lomb segment offers products with a focus on the vision care, surgical, and consumer, surgical, and ophthalmic pharmaceuticals products. The Salix segment provides gastroenterology products in the United States. The International Rx segment offers Solta products, branded and generic pharmaceutical products, OTC products, and medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia, Latin America, Africa, and the Middle East. The Ortho Dermatologics segment provides dermatological products in the United States; and Solta medical aesthetic devices internationally. The Diversified Products segment offers pharmaceutical products in the areas of neurology and other therapeutic classes, as well as generic and dentistry products in the United States. The company was formerly known as Valeant Pharmaceuticals International, Inc. and changed its name to Bausch Health Companies Inc. in July 2018. Bausch Health Companies Inc. is headquartered in Laval, Canada.

Bausch Health Companies Inc.

The significance of a company's longevity in the market

Years since IPO

Evaluation of recent trends and improvements in the company's revenue

Revenue Growth

Assessment of recent increases in earnings per share, indicating profitability

EPS Growth

Review of the company's ability to generate free cash flow over recent periods

FCF Growth

Analysis of Return on Equity, showing how effectively the company uses equity to generate profits

Examination of debt levels using Debt/Assets and Debt/EBITDA to ensure manageable leverage

Debt

COLLABORATION EXPANDS ACCESS TO SCIENCE-LED, MICROBIOME-FRIENDLY SKINCARE SOLUTIONS IN MEXICO AND ACROSS NEW MARKETS IN EMEA, INCLUDING LAUNCHES IN THE CZECH REPUBLIC, SLOVAKIA, UKRAINE, BULGARIA AND KAZAKHSTAN. LAVAL, QC, SEPT.

BAUSCH HEALTH AND YUN ANNOUNCE EXPANSION TO MEXICO AND ACROSS ADDITIONAL EMEA MARKETS

THIS YEAR'S ASPIRE HIGHER SCHOLARSHIPS ARE AWARDED TO SIX STUDENTS WHO HAVE BEEN AFFECTED BY DERMATOLOGIC CONDITIONS. LAVAL, QC, AUG. 27, 2026 /PRNEWSWIRE/ -- BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC), A GLOBAL, DIVERSIFIED PHARMACEUTICAL COMPANY, AND ITS DERMATOLOGY BUSINESS, ORTHO DERMATOLOGICS, TODAY ANNOUNCED THE RECIPIENTS OF ITS 2026 ASPIRE HIGHER SCHOLARSHIP PROGRAM.

BAUSCH HEALTH'S ORTHO DERMATOLOGICS ANNOUNCES THE 2026 ASPIRE HIGHER SCHOLARSHIP WINNERS

VAUGHAN, ONTARIO--(BUSINESS WIRE)--BAUSCH + LOMB CORPORATION (NYSE/TSX: BLCO), A LEADING GLOBAL EYE HEALTH COMPANY DEDICATED TO HELPING PEOPLE SEE BETTER TO LIVE BETTER, TODAY ANNOUNCED THAT TWO OF ITS PHARMACEUTICAL PIPELINE ASSETS  BOTH FIRST-IN-CLASS TREATMENTS  WILL ADVANCE TO NEW TRIALS BASED ON RECENT CLINICAL RESULTS. HELPING PEOPLE SEE BETTER TO LIVE BETTER STARTS WITH TACKLING THE CHALLENGES PATIENTS STILL FACE EVERY DAY, SAID BAUSCH + LOMB CEO BRENT SAUNDERS. THESE RESULTS SUPPOR.

BAUSCH + LOMB ADVANCING TWO FIRST-IN-CLASS EYE HEALTH THERAPIES BASED ON TRIAL RESULTS

FOR THE SEVENTH CONSECUTIVE YEAR, 10 STUDENTS WITH GASTROINTESTINAL DISEASE WILL EACH RECEIVE A $10,000 SCHOLARSHIP LAVAL, QC, AUG. 17, 2026 /PRNEWSWIRE/ -- BAUSCH HEALTH COMPANIES INC. (NYSE: BHC)(TSX: BHC) AND ITS GASTROENTEROLOGY (GI) BUSINESS, SALIX PHARMACEUTICALS ("SALIX"), TODAYANNOUNCED THE RECIPIENTS OF ITS 2026 SALIX GASTROINTESTINAL HEALTH SCHOLARS PROGRAM. FOR THE SEVENTH YEAR, BAUSCH HEALTH IS PROUD TO AWARD 10 DESERVING STUDENTS LIVING WITH A GI DISEASE $10,000 EACH TO FURTHER THEIR HIGHER EDUCATION.

BAUSCH HEALTH ANNOUNCES 2026 GASTROINTESTINAL HEALTH SCHOLARS PROGRAM WINNERS

LAVAL, QC, AUG. 6, 2026 /PRNEWSWIRE/ -- BAUSCH HEALTH COMPANIES INC. (NYSE: BHC)(TSX: BHC) ("BAUSCH HEALTH" OR THE "COMPANY"),TODAY ANNOUNCED THAT ITS CEO, THOMAS J.APPIO, HAS BEEN APPOINTED TO THE BOARD OF DIRECTORS OF BAUSCH + LOMB CORPORATION (NYSE: BLCO)(TSX: BLCO), A SUBSIDIARY OF BAUSCH HEALTH COMPANIES INC., EFFECTIVE AUGUST 5, 2026.

BAUSCH HEALTH CEO THOMAS J. APPIO JOINS BAUSCH + LOMB BOARD

VAUGHAN, ONTARIO--(BUSINESS WIRE)--BAUSCH + LOMB CORPORATION (NYSE/TSX: BLCO), A LEADING GLOBAL EYE HEALTH COMPANY DEDICATED TO HELPING PEOPLE SEE BETTER TO LIVE BETTER, TODAY ANNOUNCED CHANGES TO ITS BOARD OF DIRECTORS. AT THE REQUEST OF BAUSCH HEALTH COMPANIES INC. (BAUSCH HEALTH), WHICH HAS HELD A MAJORITY OWNERSHIP POSITION IN BAUSCH + LOMB SINCE ITS INITIAL PUBLIC OFFERING IN 2022 AND CURRENTLY OWNS, DIRECTLY OR INDIRECTLY THROUGH ITS WHOLLY OWNED SUBSIDIARIES, APPROXIMATELY 87% OF THE C.

BAUSCH + LOMB ANNOUNCES BOARD OF DIRECTORS UPDATE, REAFFIRMS GUIDANCE

SECOND QUARTER CONSOLIDATED REVENUES OF $2.85 BILLION, UP 13% ON A REPORTED BASIS AND 11% ON AN ORGANIC (NON-GAAP)1 BASIS OVER THE PRIOR YEAR PERIOD GAAP NET INCOME ATTRIBUTABLE TO BAUSCH HEALTH OF $258 MILLION AND GAAP NET INCOME OF $260 MILLION GAAP EARNINGS PER DILUTED SHARE ATTRIBUTABLE TO BAUSCH HEALTH OF $0.68 COMPARED TO $0.40 IN THE PRIOR YEAR PERIOD; ADJUSTED EARNINGS PER DILUTED SHARE (NON-GAAP)1 OF $1.26 COMPARED TO $0.90 IN THE PRIOR YEAR PERIOD, AN INCREASE OF 40% CONSOLIDATED ADJUSTED EBITDA ATTRIBUTABLE TO BAUSCH HEALTH (NON-GAAP)1 OF $1,075 MILLION, UP 28% ON A REPORTED BASIS OVER THE PRIOR YEAR PERIOD BAUSCH HEALTH EXCLUDING BAUSCH + LOMB SECOND QUARTER 2026 RESULTS DELIVERED THIRTEENTH CONSECUTIVE QUARTER OF YEAR-OVER-YEAR REVENUE GROWTH, WITH REVENUE UP 16% ON A REPORTED BASIS AND 13% ON AN ORGANIC (NON-GAAP)1 BASIS NET INCOME INCREASED $84 MILLION OVER THE PRIOR YEAR PERIOD, AND ADJUSTED EBITDA (NON-GAAP)1 GREW 28% GENERATED $517 MILLION IN CASH PROVIDED BY OPERATING ACTIVITIES AND $471 MILLION IN ADJUSTED CASH FLOWS FROM OPERATIONS (NON-GAAP)1  RAISING FULL-YEAR 2026 REVENUE, ADJUSTED EBITDA (NON-GAAP)1, AND ADJUSTED CASH FLOWS FROM OPERATIONS (NON-GAAP)1 GUIDANCE LAVAL, QC, JULY 29, 2026 /PRNEWSWIRE/ -- BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC) ("BAUSCH HEALTH" OR THE "COMPANY" OR "WE" OR "OUR") TODAY ANNOUNCED ITS SECOND QUARTER 2026 FINANCIAL RESULTS AND OTHER KEY UPDATES FROM THE QUARTER. "THE SECOND QUARTER MARKS OUR THIRTEENTH CONSECUTIVE QUARTER OF YEAR-OVER-YEAR GROWTH IN REVENUE AND ADJUSTED EBITDA FOR BAUSCH HEALTH, EXCLUDING BAUSCH + LOMB, REFLECTING THE STRENGTH OF OUR PORTFOLIO, DISCIPLINED EXECUTION, AND THE DEDICATION OF OUR TEAMS AROUND THE WORLD.

BAUSCH HEALTH ANNOUNCES SECOND QUARTER 2026 RESULTS, RAISES GUIDANCE

LAVAL, QC, JULY 7, 2026 /PRNEWSWIRE/ -- BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC) WILL RELEASE SECOND QUARTER 2026 FINANCIAL RESULTS AFTER MARKET CLOSE ON WEDNESDAY, JULY 29, 2026. BAUSCH HEALTH WILL HOST A LIVE CONFERENCE CALL AND WEBCAST AT 5:00 P.M.

BAUSCH HEALTH TO ANNOUNCE SECOND QUARTER 2026 RESULTS ON JULY 29, 2026

LAVAL, QC, JULY 1, 2026 /PRNEWSWIRE/ -- BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC) TODAY ANNOUNCED THAT MICHAEL GOETTLER HAS RESIGNED FROM ITS BOARD OF DIRECTORS, EFFECTIVE JUNE 30, 2026, IN CONNECTION WITH HIS APPOINTMENT AS PRESIDENT AND CHIEF EXECUTIVE OFFICER OF KNOA PHARMA LLC. "WE THANK MICHAEL FOR HIS VALUED SERVICE AND WISH HIM THE BEST IN HIS NEW ROLE," SAID JOHN A.

MICHAEL GOETTLER RESIGNS FROM BAUSCH HEALTH'S BOARD OF DIRECTORS

THERMAGE  , A PIONEER IN NON-INVASIVE SKIN TIGHTENING, WAS AWARDED THE AAA WELL-KNOWN TRADEMARK CERTIFICATION, THE HIGHEST RECOGNITION IN CHINA'S DOMESTIC TRADEMARK EVALUATION SYSTEM. LAVAL, QC, MAY 28, 2026 /PRNEWSWIRE/ -- BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC), A GLOBAL, DIVERSIFIED PHARMACEUTICAL COMPANY, AND SOLTA MEDICAL, A GLOBAL LEADER IN THE MEDICAL AESTHETICS MARKET, ARE PROUD TO ANNOUNCE THAT THEIR FLAGSHIP BRAND, THERMAGE, WAS AWARDED THE PRESTIGIOUS AAA WELL-KNOWN TRADEMARK CERTIFICATION ("AAA") BY THE CHINA TRADEMARK ASSOCIATION (CTA), A RENOWNED ACCREDITATION RESERVED FOR TOP-TIER BRANDS.

BAUSCH HEALTH'S AESTHETIC BUSINESS, SOLTA MEDICAL, EARNS PRESTIGIOUS TRADEMARK CERTIFICATION OF THERMAGE IN CHINA

LAVAL, QC, MAY 19, 2026 /PRNEWSWIRE/ -- BAUSCH HEALTH COMPANIES INC. (NYSE:BHC)(TSX:BHC) TODAY ANNOUNCED THAT SHAREHOLDERS ELECTED ALL 10 DIRECTOR NOMINEES AT ITS 2026 ANNUAL MEETING OF SHAREHOLDERS ("ANNUAL MEETING") HELD ON MAY 19, 2026, INCLUDING EIRY W. ROBERTS, M.D.

Bausch Health Companies Inc.

BHC

Price

Financial Reports

No items found.

Press Releases

Bausch Health Companies Inc.

BHC.css-1jgtvd5{-webkit-user-select:none;-moz-user-select:none;-ms-user-select:none;user-select:none;width:1em;height:1em;overflow:hidden;display:inline-block;text-align:center;-webkit-flex-shrink:0;-ms-flex-negative:0;flex-shrink:0;font-size:1.5rem;}

Price

Financial Reports

No items found.

Press Releases

BHC